The 17th International Symposium on Developmental Biotechnology (2017.10)바로가기
페이지
pp.146-146
저자
Ji-Youn Kim, Mi-Ryung Park, Hak-Jae Chung, Sung June Byun, Keon Bong Oh, Hyeon Yang, Kyung-Woon Kim
언어
영어(ENG)
URL
https://www.earticle.net/Article/A347398
원문정보
초록
영어
Dipeptidyl peptidase IV (DPP-4) is a widely distributed type II transmembrane glycoprotein with known CD26 and its expression is reported in various human cells in its extracellular domain. Recently, DPP-4 inhibitors have been widely used as a second- line therapy for type 2 diabetes because of their glucose-lowering efficacy, weight neutral effects and minimal hypoglycemia. In this study, we introduced a human DPP-4 (hDPP-4) gene into fertilized one cell pig zygotes using microinjection, and produced a piglet that over-expressed human DPP-4 gene. RT-PCR analysis showed that human DPP-4 gene was ove-rexpressed in the various tissues, respectively. Establishment of hDPP-4 transgenic fibroblast cell from ear tissue was verified by mRNA and protein expression. These results suggest that described generation of transgenic pigs that overexpressed human DPP-4. Further study is necessary to confirm whether diabetes occur in these transgenic pigs, especially insulin resistance.